Shandong Xinhua (00719): Artificial musk jasmin capsules have obtained the "Notice of Approval for Drug Supplement Application"

Shandong Xinhua (00719) has announced that recently, the company received the approval notice for the supplemental application of artificial bezoar metronidazole capsules issued by the National Medical Products Administration, approving the transfer of the marketing authorization holder for the supplement application. In March 2026, Shandong Xinhua Pharmaceutical submitted supplemental application materials for the change of marketing authorization holder to the National Medical Products Administration and recently received the approval notice for the supplemental application, with the evaluation conclusion stating that the transfer application for the marketing authorization holder complies with the relevant requirements for post-market changes of pharmaceuticals, approving the change of the marketing authorization holder for this product. This product is suitable for acute pericoronitis of wisdom teeth, localized alveolar abscess, pulpitis, apical periodontitis, etc. According to relevant statistical data, the sales revenue of artificial bezoar metronidazole capsules in public medical institutions in China in 2024 was approximately RMB 579 million.